RedHill Biopharma (RDHL) Gains from Investment Securities (2014 - 2015)
RedHill Biopharma's (RDHL) quarterly Gains from Investment Securities came in at -$889006.0 in Q4 2015, down 347.63% year-on-year from $359000.0 in Q4 2014, and down 87086.89% on a QoQ basis from $1022.0 in Q3 2015.
RedHill Biopharma (RDHL) Gains from Investment Securities (2014 - 2015) Analysis & Trends
RedHill Biopharma (RDHL) has 2 years of Gains from Investment Securities data on file, last reported at -$889006.0 in Q4 2015.
- On a quarterly basis, Gains from Investment Securities fell 347.63% year-over-year to -$889006.0 in Q4 2015; TTM through Dec 2015 was -$1.6 million, a N/A change from a year earlier, with the FY2015 full-year figure at -$888000.0, down 344.0% from the prior year.
- Gains from Investment Securities for Q4 2015 stood at -$889006.0, down from $1022.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for RDHL reached as high as $359000.0 in Q4 2014 and fell as low as -$1.1 million in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -889,006.00 |
| Dec 31, 2015 | -889,006.00 |
| Sep 30, 2015 | 1,022.00 |
| Sep 30, 2015 | 1,022.00 |
| Dec 31, 2014 | 359,000.00 |
| Dec 31, 2014 | 359,000.00 |
| Sep 30, 2014 | -1.09 Mn |
| Sep 30, 2014 | -1.09 Mn |